Real-world 6-month outcomes of minimally invasive aortic valve replacement with the EDWARDS INTUITY Elite valve system.
Aortic valve replacement
Bioprosthesis
Haemodynamics
Heart valve
Rapid-deployment valve
Sutureless valve
Journal
Interactive cardiovascular and thoracic surgery
ISSN: 1569-9285
Titre abrégé: Interact Cardiovasc Thorac Surg
Pays: England
ID NLM: 101158399
Informations de publication
Date de publication:
09 07 2022
09 07 2022
Historique:
received:
27
07
2021
revised:
18
02
2021
accepted:
01
04
2022
pubmed:
9
4
2022
medline:
22
7
2022
entrez:
8
4
2022
Statut:
ppublish
Résumé
We report on real-world safety and performance outcomes of minimally invasive rapid-deployment aortic valve replacement using the EDWARDS INTUITY Elite aortic valve system. The study valve system was used in a European, prospective, multicentre post-market study. Various procedural, haemodynamic and clinical outcomes were evaluated through 6 months of post-implant. A total of 276 patients out of 280 (98.6%) enrolments were successfully implanted with the study valve using a minimally invasive approach between February 2016 and April 2017. Of these 276 patients, 240 (87%) underwent partial sternotomy and 36 (13%) patients underwent right thoracotomy. Mean cross-clamp time was 51.9 [standard deviation (SD): 16.0] min. From baseline to 6 months, the mean effective orifice area increased from 0.8 (SD: 0.3) to 1.8 (SD: 0.6) cm2 and the mean systolic gradient decreased from 46.0 (SD: 14.1) to 8.8 (SD: 3.7) mmHg. After 6 months, 70.7% and 26.4% of patients were in New York Heart Association class I and II, respectively. Freedom from death, major bleeding, major paravalvular leak, reoperation and device explant at 6 months were 96.0%, 98.5%, 98.8%, 99.2% and 99.2%, respectively. These results demonstrate that the study valve is a safe and effective choice for patients undergoing aortic valve replacement via minimally invasive surgery. MISSION (Assessing clinical outcomes using the EDWARDS INTUITY Elite Valve System in isolated AVR using Minimally InvaSive Surgery In a EurOpean multi-ceNter, active, post-market registry). clinicaltrials.gov ID #NCT02907463.
Identifiants
pubmed: 35394527
pii: 6565358
doi: 10.1093/icvts/ivac083
pmc: PMC9631962
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT02907463']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Edwards Lifesciences
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.
Références
Interact Cardiovasc Thorac Surg. 2016 Jun;22(6):799-805
pubmed: 26976130
J Thorac Cardiovasc Surg. 2021 Sep;162(3):803-811
pubmed: 32204909
Eur J Cardiothorac Surg. 2019 Mar 1;55(3):527-533
pubmed: 30137264
Ann Thorac Surg. 2015 Jan;99(1):17-25
pubmed: 25441065
Ann Thorac Surg. 2020 Nov;110(5):1549-1556
pubmed: 32205113
Eur J Cardiothorac Surg. 2019 Oct 01;56(4):793-799
pubmed: 30820549
Cardiovasc Eng Technol. 2017 Mar;8(1):17-29
pubmed: 27873180
Eur J Cardiothorac Surg. 2020 Nov 1;58(5):1063-1071
pubmed: 32588056
J Thorac Cardiovasc Surg. 2018 Feb;155(2):575-585
pubmed: 29415382
J Thorac Cardiovasc Surg. 2008 Apr;135(4):732-8
pubmed: 18374749
Eur J Cardiothorac Surg. 2018 Oct 1;54(4):768-773
pubmed: 29617925
EuroIntervention. 2019 May 20;15(1):37-43
pubmed: 30777843
J Thorac Cardiovasc Surg. 2017 Feb;153(2):241-251.e2
pubmed: 27817951
Eur J Cardiothorac Surg. 2018 May 1;53(suppl_2):ii29-ii31
pubmed: 29370367
Eur J Cardiothorac Surg. 2017 Aug 01;52(2):281-287
pubmed: 28453629
Ann Thorac Surg. 2018 Jul;106(1):14-22
pubmed: 29630873
Ann Thorac Surg. 2017 Sep;104(3):1080-1087
pubmed: 28499651